CD274 and neoplasm: Other recent work has also suggested that loss of PTPN22 might be beneficial for anti-tumor responses, since PTPN22–/– mice showed increased tumor rejections in combination with anti-PD-L1 immunotherapy (Cubas et al., 2020).